Lymphoma

10 protocols meet the specified criteria.

  • A051901

    Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

  • A211901

    Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

  • CCTL019B2003I

    Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)

  • GO43878

    A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma

  • GRAIL-MA-002

    REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

  • JCAR017-EAP-001

    Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

  • KT-US-472-0141

    Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication

  • WVU010922

    Prospective Evaluation of Xerava (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia